Skip to main content
Top
Published in: Clinical and Experimental Nephrology 2/2016

Open Access 01-04-2016 | Original Article

Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy

Authors: Ritsuko Katafuchi, Tetsuya Kawamura, Kensuke Joh, Akinori Hashiguchi, Satoshi Hisano, Akira Shimizu, Yoichi Miyazaki, Masaharu Nagata, Seiichi Matsuo, The IgA nephropathy Study Group in Japan

Published in: Clinical and Experimental Nephrology | Issue 2/2016

Login to get access

Abstract

Background

The IgA nephropathy (IgAN) Study Group in Japan conducted a multicenter, randomized, controlled trial of tonsillectomy with steroid pulse therapy (TSP) versus steroid pulse monotherapy in patients with IgAN (UMIN Clinical Trial Registry Number; C000000384). The effects of therapies in relation to pathological severity were analyzed in this study.

Methods

The patients with IgAN, urinary protein 1.0–3.5 g/day, serum creatinine of 1.5 mg/dl or less were randomly assigned to receiving TSP (Group A) or steroid pulses alone (Group B). The primary endpoint was the disappearance of proteinuria and/or hematuria. Twenty-six biopsies in Group A and 33 in Group B were available. The histological grades (HG) according to the percentage of glomeruli with crescent or sclerosis and the Oxford classification were analyzed.

Results

The patients in Group A had a 4.32- to 12.1-fold greater benefit of disappearance of proteinuria and 3.61- to 8.17-fold greater benefit of clinical remission (disappearance of proteinuria and hematuria) than those in Group B in patients with HG2–3, acute lesions (cellular or fibrocellular crescent) affecting more than 5 % of glomeruli, chronic lesions (fibrous crescents or sclerosis) affecting more than 20 % and S1. In contrast, odds ratios for disappearance of proteinuria or clinical remission in Group A to Group B were not significant in patients with HG 1, acute lesion in 5 % or less of glomeruli, chronic lesion in 20 % or less and S0. The disappearance of hematuria showed no relation to pathological severity.

Conclusion

TSP might be better employed according to the pathological severity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hotta O, Miyazaki M, Furuta T, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.CrossRefPubMed Hotta O, Miyazaki M, Furuta T, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.CrossRefPubMed
2.
go back to reference Miura N, Imai H, Kikuchi S, et al. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460–6.CrossRefPubMed Miura N, Imai H, Kikuchi S, et al. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460–6.CrossRefPubMed
3.
4.
go back to reference Imai H, Miura N. A treatment dilemma in adult immunoglobulin A nephropathy: what is the appropriate target, preservation of kidney function or induction of clinical remission? Clin Exp Nephrol. 2012;16:195–201.CrossRefPubMedPubMedCentral Imai H, Miura N. A treatment dilemma in adult immunoglobulin A nephropathy: what is the appropriate target, preservation of kidney function or induction of clinical remission? Clin Exp Nephrol. 2012;16:195–201.CrossRefPubMedPubMedCentral
5.
go back to reference Locatelli F, Vecchio LD, Pozzi C. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors. Nat Clin Pract Nephrol. 2006;2:24–31.CrossRefPubMed Locatelli F, Vecchio LD, Pozzi C. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors. Nat Clin Pract Nephrol. 2006;2:24–31.CrossRefPubMed
6.
7.
go back to reference Kawamura T, Yoshimura M, Miyazaki Y, et al. Special IgA Nephropathy Study Group. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant. 2014;29:1546–53.CrossRefPubMedPubMedCentral Kawamura T, Yoshimura M, Miyazaki Y, et al. Special IgA Nephropathy Study Group. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant. 2014;29:1546–53.CrossRefPubMedPubMedCentral
8.
go back to reference Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed
9.
go back to reference no author. Clinical guides for immunoglobulin A (IgA) nephropathy in Japan, third version. Nihon Jinzo Gakkai Shi. 2011; 53:123–135. no author. Clinical guides for immunoglobulin A (IgA) nephropathy in Japan, third version. Nihon Jinzo Gakkai Shi. 2011; 53:123–135.
10.
go back to reference Kawamura T, Joh K, Okonogi H, et al. Special IgA Nephropathy Study Group. A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. J Nephrol. 2013;26:350–7.CrossRefPubMed Kawamura T, Joh K, Okonogi H, et al. Special IgA Nephropathy Study Group. A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. J Nephrol. 2013;26:350–7.CrossRefPubMed
11.
go back to reference Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76:534–545. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76:534–545.
12.
go back to reference Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook HT, Troyanov S, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76:546–556. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook HT, Troyanov S, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76:546–556.
13.
go back to reference Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001;38:728–35.CrossRefPubMed Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001;38:728–35.CrossRefPubMed
14.
go back to reference Li PK, Ho KK, Szeto CC, Yu L, Lai FM. Prognostic indicators of IgA nephropathy in the Chinese–clinical and pathological perspectives. Nephrol Dial Transplant. 2002;17:64–9.CrossRefPubMed Li PK, Ho KK, Szeto CC, Yu L, Lai FM. Prognostic indicators of IgA nephropathy in the Chinese–clinical and pathological perspectives. Nephrol Dial Transplant. 2002;17:64–9.CrossRefPubMed
15.
go back to reference Yu HH, Chu KH, Yang YH, et al. Genetics and immunopathogenesis of IgA nephropathy. Clin Rev Allergy Immunol. 2011;41:198–213.CrossRefPubMed Yu HH, Chu KH, Yang YH, et al. Genetics and immunopathogenesis of IgA nephropathy. Clin Rev Allergy Immunol. 2011;41:198–213.CrossRefPubMed
17.
go back to reference Kawasaki Y, Suyama K, Abe Y, et al. Tonsillectomy with methylprednisolone pulse therapy as rescue treatment for steroid-resistant IgA nephropathy in children. Tohoku J Exp Med. 2009;218:11–6.CrossRefPubMed Kawasaki Y, Suyama K, Abe Y, et al. Tonsillectomy with methylprednisolone pulse therapy as rescue treatment for steroid-resistant IgA nephropathy in children. Tohoku J Exp Med. 2009;218:11–6.CrossRefPubMed
18.
go back to reference Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883–7.CrossRefPubMed Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883–7.CrossRefPubMed
19.
go back to reference Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15:157–63.CrossRefPubMed Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15:157–63.CrossRefPubMed
20.
go back to reference Katafuchi R, Ninomiya T, Mizumasa T, Ikeda K, Kumagai H, Nagata M, Hirakata H. The improvement of renal survival with steroid pulse therapy in IgA nephropathy. Nephrol Dial Transplant. 2008;23:3915–20.CrossRefPubMedPubMedCentral Katafuchi R, Ninomiya T, Mizumasa T, Ikeda K, Kumagai H, Nagata M, Hirakata H. The improvement of renal survival with steroid pulse therapy in IgA nephropathy. Nephrol Dial Transplant. 2008;23:3915–20.CrossRefPubMedPubMedCentral
21.
go back to reference Miyazaki M, Hotta O, Komatsuda A, et al. A multicenter prospective cohort study of tonsillectomy and steroid therapy in Japanese patients with IgA nephropathy: a 5-year report. Contrib Nephrol. 2007;157:94–8.PubMed Miyazaki M, Hotta O, Komatsuda A, et al. A multicenter prospective cohort study of tonsillectomy and steroid therapy in Japanese patients with IgA nephropathy: a 5-year report. Contrib Nephrol. 2007;157:94–8.PubMed
22.
go back to reference Komatsu H, Fujimoto S, Hara S, et al. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3:1301–7.CrossRefPubMedPubMedCentral Komatsu H, Fujimoto S, Hara S, et al. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3:1301–7.CrossRefPubMedPubMedCentral
23.
go back to reference Tomino Y, Sakai H. Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, second version. Clin Exp Nephrol. 2003;7:93–7.CrossRefPubMed Tomino Y, Sakai H. Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, second version. Clin Exp Nephrol. 2003;7:93–7.CrossRefPubMed
24.
go back to reference Miyamoto T, Nishino T, Nakata T, et al. Impact of tonsillectomy combined with steroid pulse therapy on immunoglobulin A nephropathy depending on histological classification: a multicenter study. Clin Exp Nephrol. 2015. doi:10.1007/s10157-015-1131-1.PubMedCentral Miyamoto T, Nishino T, Nakata T, et al. Impact of tonsillectomy combined with steroid pulse therapy on immunoglobulin A nephropathy depending on histological classification: a multicenter study. Clin Exp Nephrol. 2015. doi:10.​1007/​s10157-015-1131-1.PubMedCentral
Metadata
Title
Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy
Authors
Ritsuko Katafuchi
Tetsuya Kawamura
Kensuke Joh
Akinori Hashiguchi
Satoshi Hisano
Akira Shimizu
Yoichi Miyazaki
Masaharu Nagata
Seiichi Matsuo
The IgA nephropathy Study Group in Japan
Publication date
01-04-2016
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 2/2016
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-015-1159-2

Other articles of this Issue 2/2016

Clinical and Experimental Nephrology 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.